V-sling
Phase 1- Indications
- Heart failure, Reduced ejection fraction heart failure
Company intelligence / Profile preview
Cardiac Success is developing the V-sling, a minimally invasive transcatheter ventricular repair device intended to treat patients with heart failure with reduced ejection fraction. The company completed a $5.2 million Series A round in 2021 to fund pre-clinical testing and its first-in-human clinical trial. The V-sling aims to transform open-heart surgery into a safer, less invasive procedure for these patients, potentially improving quality of life and reducing hospitalizations.[1][2] As of the latest available information, no published clinical results are available.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cardiac Success.